ASMB: the cashflow

MyFinsight

For the quarter ending 2025-09-30.

Cash Flow Overview

No enough data to generate the overview

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-09-30	2025-06-30
Collaboration revenue from a related party	29,834	-
ABIFive Three Six Six	7,158	-
ABIOne One Seven Nine	5,047	-
ABISix Two Five Zero	4,617	-
ABIFour Three Three Four	919	-
ABISeven Two Seven Two	2,004	-
Research And Discovery	5,839	-
Vebicorvir	0	-
Total external program expenses	25,584	-
Employee and contractor-related expenses	19,365	-
Facility and other expenses	2,614	-
Total research and development	47,563	-
General and administrative	14,188	-
Interest and other income, net	3,705	-
Income tax expense	0	-
Net loss	-28,212	-19,016
Depreciation and amortization	97	65
Stock-based compensation	3,216	1,546
Net accretion of investments in marketable debt securities	1,518	887
Non-cash rent expense	647	438
Accounts receivable from collaboration (-912 and - from a related party)	912	0
Prepaid expenses and other current assets	-81	-937
Accounts payable	1,098	158
Accrued research and development expenses	785	-582
Other accrued expenses	-1,134	-3,455
Deferred revenue from a related party	-28,922	-19,045
Operating lease liabilities	-556	-356
Net cash used in operating activities	-55,330	-40,197
Proceeds from maturities of marketable securities	83,632	60,932
Purchases of marketable securities	218,281	37,352
Purchases of property and equipment	42	0
Net cash (used in) provided by investing activities	-134,691	23,580
Proceeds from the issuance of common stock, pre-funded warrants and warrants in an underwritten offering, net of issuance costs	123,600	-
Proceeds from the issuance of common stock and warrants in private placements to a related party, net of issuance costs	42,785	0
Proceeds from the exercise of warrants	5,510	-
Proceeds from the issuance of common stock under atm equity offering program, net of issuance costs	1,922	1,922
Proceeds from the issuance of common stock under espp	357	357
Proceeds from the exercise of stock options	37	0
Proceeds from the issuance of common stock and warrants in a registered direct offering and a private placement, net of issuance costs	0	0
Net cash provided by financing activities	174,211	2,279
Net (decrease) increase in cash and cash equivalents	-15,810	-14,338
Cash and cash equivalents at beginning of period	38,344	-
Cash and cash equivalents at end of period	22,534	-

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Time Plot

Show the time plot by selecting a row from the table.

ASMB: the cashflow